SpringWorks Therapeutics, Inc.’s SWTX share price has surged by 11.08%, which has investors questioning if this is right time to sell.

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...

Teacher Retirement System of Texas increased its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 26.4% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Charles Schwab Investment Management Inc. lifted its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 0.5% during the fourth quarter, Holdings Channel reports.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Overview: SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations with rare diseases ...

SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo’s revenues alone reached $172 million in 2024, supported by ...

All told, 7% of patients treated with SpringWorks' therapy had a complete response to treatment, and 95% of side effects liked to the drug were mild (grade 1 or 2), most commonly diarrhoea, rash ...